Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
Shionogi TechnoAdvance Research Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
Vaccine. 2022 Dec 12;40(52):7520-7525. doi: 10.1016/j.vaccine.2022.10.092. Epub 2022 Nov 8.
SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4 and BA.5 have been spreading rapidly and become dominant worldwide. Here we report the homologous or heterologous booster effects of S-268019-b, a recombinant spike protein vaccine with the squalene-based adjuvant A-910823 in cynomolgus macaques. In macaques which had been primed with S-268019-b or mRNA vaccines, boosting with S-268019-b enhanced neutralizing antibodies (NAb) against ancestral SARS-CoV-2. Since boosting with the antigen without adjuvant did not efficiently restore NAb titers, adjuvant A-910823 was essential for the booster effect. Importantly, boosting with S-268019-b enhanced NAb against all of the Omicron subvariants we tested, including BA.2.12.1, BA.4 and BA.5, in comparison to two vaccine doses. Additionally, expansion of Omicron-specific B cells was confirmed after boosting with S-268019-b. These results indicate that a booster dose of S-268019-b with the adjuvant enhances the neutralization breadth.
SARS-CoV-2 的奥密克戎亚变种,如 BA.2.12.1、BA.4 和 BA.5,正在迅速传播并在全球范围内占据主导地位。在这里,我们报告了 S-268019-b(一种含有角鲨烯佐剂 A-910823 的重组刺突蛋白疫苗)在食蟹猴中的同源或异源增强效果。在已用 S-268019-b 或 mRNA 疫苗进行初免的猕猴中,用 S-268019-b 进行加强免疫可增强针对原始 SARS-CoV-2 的中和抗体(NAb)。由于用无佐剂的抗原进行加强免疫不能有效地恢复 NAb 滴度,因此佐剂 A-910823 对于增强效果至关重要。重要的是,与两剂疫苗相比,用 S-268019-b 进行加强免疫可增强对我们测试的所有奥密克戎亚变种的 NAb,包括 BA.2.12.1、BA.4 和 BA.5。此外,用 S-268019-b 进行加强免疫后,证实了奥密克戎特异性 B 细胞的扩增。这些结果表明,用佐剂增强的 S-268019-b 加强免疫剂量可提高中和广度。